open access

Vol 9, No 3 (2020)
ORIGINAL ARTICLES
Published online: 2020-03-31
Get Citation

Evaluation of Helicobacter pylori IgG levels in type 2 diabetes mellitus patients

Abolfazl Ghasemi, Neda Valizadeh, Asad Hashemi
DOI: 10.5603/DK.2020.0012
·
Clinical Diabetology 2020;9(3):179-183.

open access

Vol 9, No 3 (2020)
ORIGINAL ARTICLES
Published online: 2020-03-31

Abstract

Background. Diabetes mellitus (DM) is a common and debilitating chronic disease with increasing prevalence in the world and in Iran. Helicobacter pylori (H. pylori) is a gram-negative bacillus that causes gastritis and peptic ulcer disease and stomach cancer. It is more common in developing countries. Several studies have shown the possible association between H. pylori ifection and DM. We performed this study to evaluate H. pylori infection in type 2 diabetes mellitus (T2DM) patients in comparison to non-diabetic individuals.

Methods. In a case-control study 99 T2DM patients (aged 31 to 96 years) who referred to Urmia Imam Khomaini hospital and 96 non-diabetic controls were included. Venous blood samples were received from all participants and fasting blood glucose (FBG), HbA1c and serum H. pylori IgG levels were measured. For all individuals demographic data, including age, sex and body mass index (BMI) were recorded. H. pylori IgG levels greater than 10 U/ml was considered as H. pylori infection. H. pylori IgG serum levels of all of T2DM patients and control group were compared with each other. Data were analyzed using SPSS version 17. We used independent T-test, Chi-square and Fisher exact test for statistical analysis. The level of significance was considered as p-value < 0.05.

Results. Means age of T2DM patients and control group were 59.77 ± 13.25 and 63.43 ± 13.16 years respectively and there was not significant difference between two groups (p = 0.05). Frequency of positive H. pylori serology in T2DM patients was 69.7% and in non-diabetic group was 66.7% and there was not significant difference between two groups in this regard (p = 0.65). Mean ± SE serum H. pylori IgG levels in T2DM and non-diabetic subjects was 45.78 ± 4.82 and 44.35 ± 4.83 U/ml respectively (p = 0.83). Mean HbA1c level was significantly higher in T2DM patients compared to control group (8.40 ± 2.02 and 5.29 ± 0.45 respectively, p < 0.001).

Conclusions. According to the results of this study frequency of H. pylori infection and also serum H. pylori IgG levels in diabetic patients does not differ from non-diabetics subjects.

Abstract

Background. Diabetes mellitus (DM) is a common and debilitating chronic disease with increasing prevalence in the world and in Iran. Helicobacter pylori (H. pylori) is a gram-negative bacillus that causes gastritis and peptic ulcer disease and stomach cancer. It is more common in developing countries. Several studies have shown the possible association between H. pylori ifection and DM. We performed this study to evaluate H. pylori infection in type 2 diabetes mellitus (T2DM) patients in comparison to non-diabetic individuals.

Methods. In a case-control study 99 T2DM patients (aged 31 to 96 years) who referred to Urmia Imam Khomaini hospital and 96 non-diabetic controls were included. Venous blood samples were received from all participants and fasting blood glucose (FBG), HbA1c and serum H. pylori IgG levels were measured. For all individuals demographic data, including age, sex and body mass index (BMI) were recorded. H. pylori IgG levels greater than 10 U/ml was considered as H. pylori infection. H. pylori IgG serum levels of all of T2DM patients and control group were compared with each other. Data were analyzed using SPSS version 17. We used independent T-test, Chi-square and Fisher exact test for statistical analysis. The level of significance was considered as p-value < 0.05.

Results. Means age of T2DM patients and control group were 59.77 ± 13.25 and 63.43 ± 13.16 years respectively and there was not significant difference between two groups (p = 0.05). Frequency of positive H. pylori serology in T2DM patients was 69.7% and in non-diabetic group was 66.7% and there was not significant difference between two groups in this regard (p = 0.65). Mean ± SE serum H. pylori IgG levels in T2DM and non-diabetic subjects was 45.78 ± 4.82 and 44.35 ± 4.83 U/ml respectively (p = 0.83). Mean HbA1c level was significantly higher in T2DM patients compared to control group (8.40 ± 2.02 and 5.29 ± 0.45 respectively, p < 0.001).

Conclusions. According to the results of this study frequency of H. pylori infection and also serum H. pylori IgG levels in diabetic patients does not differ from non-diabetics subjects.

Get Citation

Keywords

diabetes mellitus type 2, Helicobacter pylori, Helicobacter pylori serology, IgG

About this article
Title

Evaluation of Helicobacter pylori IgG levels in type 2 diabetes mellitus patients

Journal

Clinical Diabetology

Issue

Vol 9, No 3 (2020)

Pages

179-183

Published online

2020-03-31

DOI

10.5603/DK.2020.0012

Bibliographic record

Clinical Diabetology 2020;9(3):179-183.

Keywords

diabetes mellitus type 2
Helicobacter pylori
Helicobacter pylori serology
IgG

Authors

Abolfazl Ghasemi
Neda Valizadeh
Asad Hashemi

References (26)
  1. Esteghamati A, Larijani B, Aghajani MH, et al. Diabetes in iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Sci Rep. 2017; 7(1): 13461.
  2. Noshad S, Afarideh M, Heidari B, et al. Diabetes care in Iran: where we stand and where we are headed. Ann Glob Health. 2015; 81(6): 839–850.
  3. Azimi-Nezhad M, Ghayour-Mobarhan M, Parizadeh MR, et al. Prevalence of type 2 diabetes mellitus in Iran and its relationship with gender, urbanisation, education, marital status and occupation. Singapore Med J. 2008; 49(7): 571–576.
  4. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. BMJ. 2001; 323(7318): 920–922.
  5. He C, Yang Z, Lu NH. Helicobacter pylori infection and diabetes: is it a myth or fact? World J Gastroenterol. 2014; 20(16): 4607–4617.
  6. Eskandarian R, Ghorbani R, Shiyasi M, et al. Prognostic role of Helicobacter pylori infection in acute coronary syndrome: a prospective cohort study. Cardiovasc J Afr. 2012; 23(3): 131–135.
  7. Shi WJ, Liu W, Zhou XY, et al. Associations of Helicobacter pylori infection and cytotoxin-associated gene A status with autoimmune thyroid diseases: a meta-analysis. Thyroid. 2013; 23(10): 1294–1300.
  8. Asadi-Pooya AA, Dehghani SM, Petramfar P, et al. Helicobacter pylori infection in patients with epilepsy. Seizure. 2012; 21(1): 21–23.
  9. Nielsen HH, Qiu J, Friis S, et al. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol. 2012; 19(6): 864–869.
  10. Roubaud-Baudron C, Krolak-Salmon P, Quadrio I, et al. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiol Aging. 2012; 33(5): 1009.e11–1009.e19.
  11. Kayar Y, Pamukçu Ö, Eroğlu H, et al. Relationship between Helicobacter pylori infections in diabetic patients and inflammations, metabolic syndrome, and complications. Int J Chronic Dis. 2015; 2015: 290128.
  12. Serghei C, Emilia T, Natalia F. Helicobacter pylori and type 2 diabetes mellitus: searching for the links. Russian Open Medical Journal. 2016; 5(2).
  13. Chung GE, Heo NJu, Park MJ, et al. Helicobacter pylori seropositivity in diabetic patients is associated with microalbuminuria. World J Gastroenterol. 2013; 19(1): 97–102.
  14. Demir M, Gokturk HS, Ozturk NA, et al. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci. 2008; 53(10): 2646–2649.
  15. Anastasios R, Goritsas C, Papamihail C, et al. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med. 2002; 13(6): 376.
  16. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. Nat Rev Endocrinol. 2011; 8(4): 228–236.
  17. Jafarzadeh A, Rezayati MT, Nemati M. Helicobacter pylori seropositivity in patients with type 2 diabetes mellitus in south-east of Iran. Acta Med Iran. 2013; 51(12): 892–896.
  18. Bener A, Micallef R, Afifi M, et al. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol. 2007; 18(4): 225–229.
  19. Devrajani BR, Shah SZ, Soomro AA, et al. Type 2 diabetes mellitus: A risk factor for Helicobacter pylori infection: A hospital based case-control study. Int J Diabetes Dev Ctries. 2010; 30(1): 22–26.
  20. Bajaj S, Rekwal L, Misra SP, et al. Association of helicobacter pylori infection with type 2 diabetes. Indian J Endocrinol Metab. 2014; 18(5): 694–699.
  21. Zojaji H, Ataei E, Sherafat SJ, et al. The effect of the treatment of Helicobacter pylori infection on the glycemic control in type 2 diabetes mellitus. Gastroenterol Hepatol Bed Bench. 2013; 6(1): 36–40.
  22. Wada Y, Hamamoto Y, Kawasaki Y, et al. The Eradication of Helicobacter pylori does not Affect Glycemic Control in Japanese Subjects with Type 2 Diabetes. Jpn Clin Med. 2013; 4: 41–43.
  23. Vafaeimanesh J, Rajabzadeh R, Ahmadi A, et al. Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens. Arab J Gastroenterol. 2013; 14(2): 55–58.
  24. Quatrini M, Boarino V, Ghidoni A, et al. Helicobacter pylori prevalence in patients with diabetes and its relationship to dyspeptic symptoms. J Clin Gastroenterol. 2001; 32(3): 215–217.
  25. Patel SK, Pratap CB, Jain AK, et al. Diagnosis of Helicobacter pylori: what should be the gold standard? World J Gastroenterol. 2014; 20(36): 12847–12859.
  26. Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of Helicobacter pylori infection: Current options and developments. World J Gastroenterol. 2015; 21(40): 11221–11235.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl